MedTrace Logo

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

NCT04312841 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-02-28

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection.

Conditions

  • B-Cell Prolymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Peripheral T-Cell Lymphoma
  • Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Sezary Syndrome
  • T-Cell Prolymphocytic Leukemia

Interventions

DRUG

Letermovir

Given PO

Sponsors & Collaborators

Principal Investigators

  • John C Reneau, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2023-11-24
Completion
2024-04-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04312841 on ClinicalTrials.gov